Breast Cancer

Mar 12, 2019

Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase...

Jan 11, 2019

Breast cancer develops when breast tissue cells grow abnormally and multiply. In essence, the hormones-- estrogen and progesterone-- and excess levels of human epidermal growth factor receptor 2 (HER2) protein are the known drivers of breast cancer. By testing samples of breast cancer tissue for hormone receptors a...

Sep 07, 2018

New areas of cancer treatment pop up every now and then without escaping our attention. And this time, it is—getting drugs directly into cancer tumors using Nanoparticles. If the buzz doing the rounds in the industry circles is to be believed, then a new cancer therapy, which will use Nanoparticles to deliver combi...

Aug 04, 2017

The discovery of Cyclin Dependent Kinases (CDKs) is a result of increasing number of cancer cases worldwide. The development of CDKs has changed the paradigm for cancer treatment and it has gradually become an interesting area of research in oncology. The research on CDK inhibitors gained momentum because of the fre...

Jun 06, 2017

Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—a...

Mar 16, 2017

GSK consolidates DT and TT vaccine production in Hungary plant, adding 100 jobs With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary as well as Germany. GlaxoSmithKline said on Monday that it would invest £40 m...

Feb 03, 2017

Cancer is the leading cause of morbidity and mortality worldwide and one in every seven deaths is due to cancer. It has the worst incidence and mortality statistics. According to the International Agency for Research on Cancer (IARC), an estimated 14.1 million new cases of cancer occur with mortality of 8.2 million ...

Nov 30, 2016

Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called antibody–drug conjugates (ADCs), is working its way through clinical trials. The concept that underlies these drugs is s...

Sep 14, 2016

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2...

Mar 03, 2015

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...